Shun Wang1, Jun Jiang2, Chao Zhang3, Xuhua Zhang1, Chuanxin Wang4. 1. Department of Clinical Laboratory, The Second Hospital, Shandong University, Jinan, Shandong, China. 2. Department of Neurosurgery, The Second Hospital, Shandong University, Jinan, Shandong, China. 3. Department of Clinical Laboratory, The Qingdao No.9 People's Hospital, Qingdao, Shandong, China. 4. Department of Clinical Laboratory, The Second Hospital, Shandong University, Jinan, Shandong, China. Electronic address: cxwang@sdu.edu.cn.
Abstract
BACKGROUND: LincRNA-p21 is involved in the initiation and progression of many human diseases. We aimed to investigate the expression of LincRNA-p21 in different types of liver diseases. METHODS: Serum from patients with primary liver diseases (chronic HBV or HCV infection, hepatitis B virus-related cirrhosis, hepatitis B virus-related HCC, non-HBV/HCV-related HCC, alcoholic liver disease) and HBV negative liver metastatic cancer and control healthy individuals was collected and serum lincRNA-p21 levels were determined by RT-qPCR. Clinicopathological characteristics of the patients were also recorded. RESULTS: Serum lincRNA-p21 levels in patients with chronic HBV infection, hepatitis B cirrhosis, hepatitis B virus-related HCC, chronic hepatitis B virus infection, non-HBV/HCV-related HCC, and alcoholic liver disease were higher than those in the control individuals (P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001 and P = 0.002, respectively). The serum lincRNA-p21 level was not significantly different between patients with HBV negative liver metastatic cancer and the normal control (P = 0.80). LincRNA-p21 level was negatively correlated with HBV DNA (P = 0.02), ALT (P = 0.01) and AST (P = 0.01) in patients with liver disease, but not correlated with gender (P = 0.24), age (P = 0.11) and AFP level (P = 0.84). Serum lincRNA-p21 in hepatocellular carcinoma patients was higher than that in liver metastatic cancer patients (P < 0.001). CONCLUSION: Serum lincRNA-p21 may serve as a potential biomarker for liver cell damage in patients with hepatitis virus infection, hepatitis B cirrhosis, HBV-related HCC and alcoholic liver disease.
BACKGROUND:LincRNA-p21 is involved in the initiation and progression of many human diseases. We aimed to investigate the expression of LincRNA-p21 in different types of liver diseases. METHODS: Serum from patients with primary liver diseases (chronic HBV or HCV infection, hepatitis B virus-related cirrhosis, hepatitis B virus-related HCC, non-HBV/HCV-related HCC, alcoholic liver disease) and HBV negative liver metastatic cancer and control healthy individuals was collected and serum lincRNA-p21 levels were determined by RT-qPCR. Clinicopathological characteristics of the patients were also recorded. RESULTS: Serum lincRNA-p21 levels in patients with chronic HBV infection, hepatitis B cirrhosis, hepatitis B virus-related HCC, chronic hepatitis B virus infection, non-HBV/HCV-related HCC, and alcoholic liver disease were higher than those in the control individuals (P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001 and P = 0.002, respectively). The serum lincRNA-p21 level was not significantly different between patients with HBV negative liver metastatic cancer and the normal control (P = 0.80). LincRNA-p21 level was negatively correlated with HBV DNA (P = 0.02), ALT (P = 0.01) and AST (P = 0.01) in patients with liver disease, but not correlated with gender (P = 0.24), age (P = 0.11) and AFP level (P = 0.84). Serum lincRNA-p21 in hepatocellular carcinomapatients was higher than that in liver metastatic cancerpatients (P < 0.001). CONCLUSION: Serum lincRNA-p21 may serve as a potential biomarker for liver cell damage in patients with hepatitis virus infection, hepatitis B cirrhosis, HBV-related HCC and alcoholic liver disease.
Authors: Marco Russano; Andrea Napolitano; Giulia Ribelli; Michele Iuliani; Sonia Simonetti; Fabrizio Citarella; Francesco Pantano; Emanuela Dell'Aquila; Cecilia Anesi; Nicola Silvestris; Antonella Argentiero; Antonio Giovanni Solimando; Bruno Vincenzi; Giuseppe Tonini; Daniele Santini Journal: J Exp Clin Cancer Res Date: 2020-05-27